ALX ONCOLOGY HOLDINGS INC
For the period ended Dec 31, 2023. Filed Mar 7, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 7, 2024
ALXO$1.11-13.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statem ents of Cash Flows
(in thousands)
| Year Ended | |||
|---|---|---|---|
| December 31, | |||
| 2023 | 2022 | 2021 | |
| Operating activities | |||
| Net loss | $(160,805) | $(123,482) | $(83,463) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Depreciation and amortization | 836 | 342 | 51 |
| Non-cash lease costs | 1,272 | 1,124 | 685 |
| Acquired in-process research and development | — | — | 4,739 |
| Stock-based compensation | 26,273 | 23,839 | 13,914 |
| Net amortization of premiums and accretion of discounts on investments | (6,487) | (940) | — |
| Accretion of term loan discount and issuance costs | 250 | 44 | — |
| Changes in operating assets and liabilities | |||
| Prepaid expenses and other current assets | (1,291) | (1,476) | (1,662) |
| Other assets | 1,366 | 750 | (9,682) |
| Accounts payable | 458 | 4,506 | 3,290 |
| Payable and accrued liabilities due to related party | (1,107) | 20 | 1,419 |
| Accrued expenses and other current liabilities | 11,224 | 7,027 | 3,306 |
| Other non-current liabilities | (2,353) | (977) | (698) |
| Net cash used in operating activities | (130,364) | (89,223) | (68,101) |
| Investing activities | |||
| Purchase of investments | (246,629) | (376,789) | — |
| Maturities of investments | 292,560 | 142,800 | — |
| Purchase of property and equipment | (1,274) | (1,427) | (666) |
| Acquisition of in-process research and development | — | — | (4,257) |
| Net cash provided by (used in) investing activities | 44,657 | (235,416) | (4,923) |
| Financing activities | |||
| Proceeds from equity offerings, net of underwriter discounts ($3.8 million) and issuance costs ($0.6 million) | 58,887 | — | — |
| Proceeds from exercise of stock options under equity incentive plan | 269 | 567 | 2,551 |
| Proceeds from issuance of common stock under employee stock purchase plan | 523 | 336 | 202 |
| Principal payments on finance leases | (388) | (388) | (281) |
| Proceeds from issuance of term loan, net | — | 10,000 | — |
| Payments of debt issuance costs | — | (655) | — |
| Net cash provided by financing activities | 59,291 | 9,860 | 2,472 |
| Net decrease in cash, cash equivalents and restricted cash | (26,416) | (314,779) | (70,552) |
| Cash, cash equivalents and restricted cash at beginning of year | 48,888 | 363,667 | 434,219 |
| Cash, cash equivalents and restricted cash at end of period | $22,472 | $48,888 | $363,667 |
| Supplemental disclosure | |||
| Cash paid for interest | $1,177 | $103 | $11 |
| Cash paid for taxes | $— | $— | $274 |
| Supplemental disclosure of non-cash investing and financing activities | |||
| Purchase of property and equipment in accounts payable and accrued expenses | $1,407 | $2,145 | $237 |
| Acquisition of in-process research and development in accounts payable and accrued expenses | $— | $— | $482 |
| Right-of-use asset acquired under operating leases | $— | $4,613 | $1,780 |
| Right-of-use asset acquired under finance leases | $2,600 | $— | $776 |
| Reconciliation of cash and cash equivalents and restricted cash: | |||
| Cash and cash equivalents | $22,406 | $48,822 | $363,667 |
| Restricted cash (included in other assets) | 66 | 66 | — |
| Total cash and cash equivalents and restricted cash | $22,472 | $48,888 | $363,667 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.